![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » 3-IN-1 AIDS TREATMENT COULD EASE TREATMENT REGIMENS IN AFRICAN COUNTRIES
3-IN-1 AIDS TREATMENT COULD EASE TREATMENT REGIMENS IN AFRICAN COUNTRIES
July 7, 2006
A generic three-in-one anti-AIDS pill, recently approved by the FDA, could greatly ease daily treatment regimens for patients in African countries. The fixed-dose combination tablet, manufactured by Aurobindo Pharma, an Indian generic drug company, will be available for purchase and distribution under the President's Emergency Plan for AIDS Relief (PEPFAR).
PEPFAR is a $15 billion initiative, launched by President Bush in 2003, for the prevention, treatment and care of HIV/AIDS in 12 African countries and the Caribbean.
Although it was not yet clear how cost-effective the new drug would be, HIV-positive people would need to take only one pill twice a day.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct